### Controlled Substance and Drug Code Table

<table>
<thead>
<tr>
<th>Controlled Substance</th>
<th>Drug Code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lysergic acid diethylamide</td>
<td>7315</td>
<td>I</td>
</tr>
<tr>
<td>5-Methoxy-N,N-dimethyltryptamine.</td>
<td>7431</td>
<td>I</td>
</tr>
<tr>
<td>Tapentadol</td>
<td>9780</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans to import the listed controlled substances as finished dosage units for use in clinical trials. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

**Claude Redd,**
*Acting Deputy Assistant Administrator.*

[FR Doc. 2023–17136 Filed 8–9–23; 8:45 am]

**BILLING CODE 4410–09–P**

### DEPARTMENT OF JUSTICE

#### Drug Enforcement Administration

[Docket No. DEA–1242]

**Bulk Manufacturer of Controlled Substances Application: Continuous Pharmaceuticals**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Continuous Pharmaceuticals has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before October 10, 2023. Such persons may also file a written request for a hearing on the application on or before October 10, 2023.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on July 6, 2023, Continuous Pharmaceuticals, 256 West Cummings Park, Woburn, Massachusetts 01801, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

<table>
<thead>
<tr>
<th>Controlled Substance</th>
<th>Drug Code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fentanyl</td>
<td>9801</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans to bulk manufacture the above listed controlled substances for research and development purposes only. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

**Claude Redd,**
*Acting Deputy Assistant Administrator.*

[FR Doc. 2023–17138 Filed 8–9–23; 8:45 am]

**BILLING CODE 4410–09–P**

### DEPARTMENT OF JUSTICE

#### Drug Enforcement Administration

[Docket No. DEA–1244]

**Bulk Manufacturer of Controlled Substances Application: Continuus Pharmaceuticals**

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** Continuus Pharmaceuticals has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before September 11, 2023. Such persons may also file a written request for a hearing on the application on or before September 11, 2023.

**ADDRESSES:** The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.33(a), this is notice that on July 14, 2023, Chattem Chemicals, 3801 Saint Elmo Avenue, Chattanooga, Tennessee 37409–1237, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

<table>
<thead>
<tr>
<th>Controlled Substance</th>
<th>Drug Code</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methamphetamine</td>
<td>1105</td>
<td>II</td>
</tr>
<tr>
<td>4-Anilino-N-phenethyl-4-piperidine (ANPP)</td>
<td>8333</td>
<td>II</td>
</tr>
<tr>
<td>Phenylacetone</td>
<td>8501</td>
<td>II</td>
</tr>
<tr>
<td>Cocaine</td>
<td>9041</td>
<td>II</td>
</tr>
<tr>
<td>Poppy Straw Concentrate</td>
<td>9670</td>
<td>II</td>
</tr>
<tr>
<td>Tapentadol</td>
<td>9780</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans to bulk manufacture the above listed controlled substances for sale to its customers. The company plans to import an intermediate of Tapentadol (9780), to bulk manufacture Tapentadol for distribution to its customers. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug
Administration-approved or non-approved finished dosage forms for commercial sale.

Claude Redd,
Acting Deputy Assistant Administrator.

[FR Doc. 2023–17139 Filed 8–9–23; 8:45 am]

BILLING CODE P

NEIGHBORHOOD REINVESTMENT CORPORATION

Sunshine Act Meetings

TIME AND DATE: 2:00 p.m., Thursday, August 17, 2023.

PLACE: 1255 Union Street NE, Fifth Floor, Washington, DC 20002.

STATUS: Parts of this meeting will be open to the public. The rest of the meeting will be closed to the public.

MATTERS TO BE CONSIDERED: Regular Board of Directors meeting.

The General Counsel of the Corporation has certified that in his opinion, one or more of the exemptions set forth in the Government in the Sunshine Act, 5 U.S.C. 552b(c)(2) and (4) permit closure of the following portion(s) of this meeting:

- Executive Session

Agenda

I. CALL TO ORDER
II. Sunshine Act Approval of Executive (Closed) Session
III. Executive Session: Report from CEO
IV. Executive Session: Report from CFO
V. Executive Session: GAO Workplan
VI. Executive Session: General Counsel Report
VII. Executive Session: CIO Report
VIII. Executive Session: NeighborWorks Compass Update
IX. Action Item Resolution of Recognition of Service for Chairman Gruenberg
X. Action Item Approval of Meeting Minutes
XI. Action Item FY2024 Preliminary Spend Plan
XII. Discussion Item August 3rd Special Audit Committee Report
XIII. Discussion Item Annual Ethics Review Follow Up
XIV. Discussion Item Professional Learning and Event Management Solution
XV. Discussion Item Atlanta Office Lease
XVI. Management Program Background and Updates
XVII. Adjournment

PORTIONS OPEN TO THE PUBLIC: Everything except the Executive Session.

PORTIONS CLOSED TO THE PUBLIC: Executive Session.

CONTACT PERSON FOR MORE INFORMATION:
Lakeyia Thompson, Special Assistant, (202) 524–9040; lthompson@nw.org.

Lakeyia Thompson,
Special Assistant.

[FR Doc. 2023–17215 Filed 8–8–23; 11:15 am]

BILLING CODE 7570–02–P

NUCLEAR REGULATORY COMMISSION

[NRC–2023–0112]

Discontinuation of the State of New York’s Sealed Source and Device Evaluation and Approval Authority

AGENCY: Nuclear Regulatory Commission.

ACTION: Discontinuation of the State of New York’s regulatory authority and reassumption of U.S. Nuclear Regulatory Commission’s authority.

SUMMARY: Notice is hereby given that effective August 9, 2023, the U.S. Nuclear Regulatory Commission (NRC) has assumed regulatory authority to evaluate and approve sealed source and device (SS&D) applications in the State of New York and approved the Governor of the State of New York’s request to relinquish this authority.

DATES: The NRC has assumed regulatory authority for evaluating and approving SS&D applications on August 9, 2023.

ADDRESSES: Please refer to Docket ID NRC–2023–0112 when contacting the NRC about the availability of information regarding this document. You may obtain publicly available information related to this document using any of the following methods:

- Federal Rulemaking Website: Go to https://www.regulations.gov and search for Docket ID NRC–2023–0112. Address questions about Docket IDs in Regulations.gov to Stacy Schumann; telephone: 301–415–0624; email: Stacy.Schumann@nrc.gov. For technical questions, contact the individuals listed in the FOR FURTHER INFORMATION CONTACT section of this document.

- NRC’s Agencywide Documents Access and Management System (ADAMS): You may obtain publicly available documents online in the ADAMS Public Documents collection at https://www.nrc.gov/reading-rm/adams.html. To begin the search, select “Begin Web-based ADAMS Search.” For problems with ADAMS, please contact the NRC’s Public Document Room (PDR) reference staff at 1–800–397–4209, 301–415–4737, or by email to PDR.Resource@nrc.gov. The ADAMS accession number for each document referenced (if it is available in ADAMS) is provided the first time that it is mentioned in this document.

- NRC’s PDR: The PDR, where you may examine and order copies of publicly available documents, is open by appointment. To make an appointment to visit the PDR, please send an email to PDR.Resource@nrc.gov or call 1–800–397–4209 or 301–415–4737, between 8 a.m. and 4 p.m. eastern time (ET), Monday through Friday, except Federal holidays.

FOR FURTHER INFORMATION CONTACT:


SUPPLEMENTARY INFORMATION: Section 274b. of the Atomic Energy Act (AEA) of 1954, as amended, provides the authority for NRC to enter into agreements with States that allow the States to assume, and the NRC to discontinue, regulatory authority over specified AEA radioactive materials and activities. On October 15, 1962, New York entered a section 274b. Agreement with the Atomic Energy Commission (the predecessor regulatory agency to the NRC) to regulate source material, byproduct material, and special nuclear material in quantities not sufficient to form a critical mass. This Agreement also provides the State regulatory authority to evaluate and approve SS&D applications.

On May 9, 2023, the NRC received a letter from New York Governor Kathy Hochul (ADAMS Accession No. ML23131A254) requesting discontinuation of the State’s regulatory authority to evaluate and approve SS&D applications and for reassumption of this authority by the NRC. The Commission approved the request and has notified the State of New York that effective August 9, 2023, the NRC has reassumed authority to evaluate and approve SS&D applications within the State (ADAMS Accession No. ML23138A033). The State of New York will retain authority to regulate the manufacture and use of SS&Ds within the State in accordance with its section 274b. Agreement with the NRC.


For the Nuclear Regulatory Commission.

Brooke P. Clark,
Secretary of the Commission.

[FR Doc. 2023–16932 Filed 8–9–23; 8:45 am]

BILLING CODE 7590–01–P